This year’s hot topics include novel approaches in the fields of infection research, oncology and immunology. In addition, exciting projects relating to the vascular system and neurodegenerative diseases as well as innovative biomarkers will be presented. Ascenion’s partners contribute a total of eight projects:
- A1 Overcoming resistance - Novel inhibitors of virulence factor LasB of Pseudomonas aeruginosa
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - A2 Novel Inhibitors of Cytomegalovirus
Helmholtz Centre for Infection Research - A3 Biodynamers enhance drug delivery
Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) - A4 Efficient, adjuvant-free mucosal vaccination via IgA feedback loop
Research Center Borstel - Leibniz Lung Center - A5 TCR/CD3-Specific CAR NK-92 Cells for Purification of TCR-Modified Cell Products
Charité - Universitätsmedizin Berlin - A6 The CXCR3ALT-CXCL11 Chemokine System for Therapeutic Use in Solid Cancer
Charité - Universitätsmedizin Berlin - A7 Novel Diagnostic for Liver Diseases
Hannover Medical School - A8 Arming oncolytic viruses using Membrane associated T-Cell activators (MATEs)
Hannover Medical School
A further program highlight is BioVaria’s dedicated Startup Pitch & Partner program. It provides attractive opportunities for entrepreneurs and venture capitalists, with interactive pitches and speed dating between startups and investors. Due to the positive feedback, the Early-stage Innovations stream, first tested in 2023, will become a permanent program item. Researchers will present very early-stage projects, including those from Ascenion's Life Science Digital Hub, which are funded as part of GO-Bio initial.
Don’t miss your chance, join in!
This year’s selected start-ups will be unveiled soon. Stay tuned!